Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nilotinib after adjuvant imatinib in localized GIST (phase II)
2010-022713-26Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Primary endpoint: Proportion of patients recurrence-free at Month 12. Started Mar 2011; status: completed.
02
Drugs
nilotinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2010-022713-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022713-26.